RxDoctor Payments Data

Maria Lopez, MD

Cardiology · Daytona Beach, FLNPI 1124088133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Medtronic at 27.8% of the total. Reporting peaked in 2019 at $391 and has fallen 59.1% since, to $160 in 2025.

$1,078in general payments, 2019–2025

Across 20 payments — averaging $53.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$300
  • Abiomed$250
  • Regeneron$128
  • Edwards Lifesciences$101
  • Shockwave Medical, Inc$84
  • Cardiovascular Systems Inc.$62
  • plus $153 from 6 others

What the payments were for

  • Food & beverage$1,06198%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,078 in reported general payments places this provider in the 55th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$166,587
Medicare patients
1,535
Services billed
3,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban258$306,493
XareltoRivaroxaban108$127,511
EntrestoSacubitril/Valsartan59$73,699
Repatha SureclickEvolocumab61$46,976
FarxigaDapagliflozin Propanediol39$32,690
Praluent PenAlirocumab15$9,163
NexletolBempedoic Acid15$6,159
Metoprolol Succinate334$4,375
Rosuvastatin Calcium323$3,993
Atorvastatin Calcium439$3,915
Ezetimibe139$3,374
Amiodarone Hcl65$3,371
Telmisartan106$2,936
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$1,946
ClopidogrelClopidogrel Bisulfate114$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$12$73,69959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 45 cardiology providers in Florida.

Other cardiology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →